Introduction
Maintaining the pulpally involved deciduous teeth in a healthy state until the time of normal exfoliation remains to be one of the challenges for pedodontics. Several materials have become popular as pulpotomy medicaments (1). The first time formaldehyde containing medicaments were used was in 1874, Formocresol (FC) (a mixture of equal parts of tricresol and formalin) has been used as the most common capping material for pulp fixation for many years (1,2). Success rate of FC pulpotomy has been 70-97% in the last decades. Concerns have been raised about the toxicity, potential carcinogenicity, cytotoxicity, allergenicity, systemic disturbances, and the possibility of affecting the permanent successors (2-5). FC in pulpotomy has been replaced with sulfate ferric, electro surgery, hydroxyapatite, bone morphogenic protein, laser, and mineral trioxide aggregate (MTA) (6-8). MTA is a biocompatible material which has been proposed as a potential medicaments for pulpotomy in primary teeth (1,5,7-9). In many studies, the qualities of the results are affected by lack of adequate samples, poor design and inappropriate case selection. This makes the
Table 1. The key words used in the Medline search

| Key words                        | Results (n) |
|----------------------------------|-------------|
| 1 pulpotomy                      | 1674        |
| 2 dental pulp exposure           | 571         |
| 3 formocresol                    | 340         |
| 4 formocresols                   | 329         |
| 5 MTA                            | 1276        |
| 6 mineral trioxide aggregate     | 353         |
| 7 3 & 1                          | 224         |
| 8 4 & 1                          | 201         |
| 9 3 & 2                          | 21          |
| 10 4 & 2                         | 20          |
| 11 5 & 1                         | 28          |
| 12 6 & 1                         | 39          |
| 13 5 & 2                         | 9           |
| 14 1 & 2                         | 16          |
| 15 (7 or 9) & (11 or 13)         | 4           |
| 16 (7 or 9) & (12 or 14)         | 15          |
| 17 (8 or 10) & (11 or 13)        | 8           |
| 18 (8 or 10) & (12 or 14)        | 12          |

Table 2. Inclusion and exclusion criteria

| Inclusion criteria                                                                 |
|-----------------------------------------------------------------------------------|
| 1- All selected teeth were human primary molars with vital pulps which have exposed |
| 2- All selected teeth had at least 6 months follow up.                             |
| 3- All selected teeth had no clinical or radiographic sign or symptoms             |
| 4- All selected teeth were restorable with stainless steel crowns or amalgam.    |
| 5- The outcome was evaluated by clinical symptoms and radiographic evaluation.   |
| 6- All cases were regarded as a failure when one or more of the following signs    |
| 7- All the studies were assessed separately and the quality of studies used       |
| 8- The study list was obtained by using PubMed (1960-March 2008), EMBASE (1984-    |
| 9- The key words used are provided in                                           |
| 10- The study was randomized clinic trial?                                       |
| 11- Different treatment methods                                                   |
| 12- In vitro, retreat or animal studies, or histological evaluation without clinical |
| 13- No comparison between MTA and formocresol                                     |
| 14- The article could not be located.                                            |

Materials and Methods

The study list was obtained by using PubMed (1960-March 2008), EMBASE (1984-March 2008), Scopus (1996-March 2008), Science Citation Index (SCI) (1995-March 2008), Iran Medex (2004-March 2008), Google Scholar (1996-March 2008), the Cochrane library (1999-March 2008) and also hand searches through dental journals approved by the Iranian Ministry of Health. The key words used are provided in Table 1. Only those papers which met the inclusion criteria’s were accepted. The search ended in March 2008 and languages of the search were limited to English and Persian. Inclusion and exclusion criteria’s have been listed in Table 2. Each study was seperately assessed by at least two reviewers.

Results

Studies with 1 year follow up: Heterogeneity test suggested no significant difference in overall success rate (P=0.55) than when a fixed model
(Peto odds ratio) was used to aggregate data of these three studies. Findings of this meta-analysis showed that the success rate of MTA was comparable with FC and there was no significant difference between them (P=0.52) (Figure 1). Also Begg’s rank correlation showed no publication bias (P=0.6) (Figure 2).

All studies: The results of the heterogeneity test suggests that the MTA and FC groups were significantly heterogeneous (P=0.02) next a random effect model was used to aggregate data of all included studies. Meta-analysis showed that success rate of MTA is superior to FC (P=0.004; CI: 1.494-8.369) (Figure 3). Begg’s rank correlation showed no publication bias (P=0.14) (Figure 4).

In comparison of two upper groups of study, it seems that time of follow up may influence the effect size of studies; therefore a meta regression analysis carried out to determine the effect of time. Results of this regression showed that the follow up intervals have no effect on the overall success rates. (P=0.96 CI: -1.56 to 1.50) (Figure 5).

Discussion
In this review the clinical and radiographic success rates of MTA were superior to FC. MTA is a biocompatible material which provides a biological seal and has been proposed as a potential medicaments for pulpotomy in primary teeth (1,2,9,12,13).

As there are limited number of studies available and sometimes different or even controversial results, meta-analysis is a good option to provide consistent results and suggestions for clinical practice. This meta-analysis evaluated the prognosis of pulpotomy in primary molar with FC versus MTA clinically and radiographically. We have listed our findings in Table 3. All 8 studies demonstrated that the case was regarded as failure in presence of one or more of the following signs: pain, swelling, furcation radiolucency, periapical bone destruction and sinus tract. Periodontal ligament space widening was not
identified as a failure in almost all studies except Jabbarifar (14) and Agamy (15). We did not include PDL widening in radiographs as a failure. Internal root resorption was identified as a failure in almost all included studies except Holan et al. (4). They argued that internal root resorption should be regarded as failure only if the process reached the root’s outer surface, and induced an inflammatory process in the periodontal ligament and surrounding bone. In this meta-analysis, internal root resorption was seen as a failure result. MTA used in Jabbarifar’s study (14) was ProRoot MTA, Kosari et al. (16) used Iranian MTA, and Agamy (15) compared relative success of gray MTA and white MTA. In this meta-analysis, there was no difference between gray and white MTA.

Pulp canal obliteration (PCO) was the most common radiographic finding in both groups. PCO is the result of odontoblastic activity and suggests that the tooth is retaining some degree of vitality (17-19).

Following points affect the final degree of reliability of meta-analysis:

- **A)** The randomization method will exclude subjective interference in case selection and distribution. Except Edilman et al. (17), Jabbarifar et al. (14), Holan et al. (4), Aienechi et al. (20), and Farsi et al. (21) studies failed to describe their ways of randomization clearly.
- **B)** Allocation concealing, (ie, patient and outcome assessor were blinded to the treatments allocation), will guarantee an accurate assessment. This was reported only in the studies of Edileman et al. (17), Holan et al. (4), Agamy et al. (15), and Jabbarifar et al. (14).
- **C)** A small sample size will lead to decreased reliability, whereas a large one will cause the difficulties of trial control and obtaining long term data, as well as increased cost and time.
- **D)** Deciduous teeth have a shorter life span, so studies with longer follow up will be at the risk of losing case information. Longer observation periods may lead to observed lower success rates than shorter times. In the 8 studies there were different observation periods, a minimum of 6 months was required as part of the inclusion criteria in this meta-analysis.
In Pengle et al. (22) meta-analysis study, 6 studies were included for meta-analysis and their results concurred with ours. The pool of data was taken from different sources in Pengle's study (including the Iranian Ministry of Health approved dental journals). Moreover this information was collected two years after completing Pengle's study.

**Conclusion**

Based on the present evidence, MTA can be used as a suitable replacement for FC in primary teeth especially in young children with multiple teeth requiring pulpotomy treatment.

**References**

1. Naik S, Hegde AM. Mineral trioxide aggregate as a pulpotomy agent in primary molars: An in vivo study. J Indian Soc Pedod Prev Dent 2005;23:13-6.
2. Antar F, Bacho R, Abi Hatem G, Ghosn Z. Is formocresol still the medication of choice for pulpotomies in primary teeth? A literature review. Lebanes J of Dental Medicine 2004;3:53.
3. Rölling I, Thyrlstrup A. A 3-year clinical follow-up study of pulpotomized primary molars treated with the formocresol technique. Scand J Dent Res 1975;83:47-53.
4. Holan G, Eidelman E, Fuks AB. Long-term evaluation of pulpotomy in primary molars using mineral trioxide aggregate or formocresol. Pediatr Dent 2005;27:129-36.
5. Roberts JF. Treatment of vital and non-vital primary molar teeth by one-stage formocresol pulpotomy: clinical success and effect upon age at exfoliation. Int J Paediatr Dent 1996;6:1-5.
6. Avram DC, Pulver F. Pulpotomy medicaments for vital primary teeth. Surveys to determine use and attitudes in pediatric dental practice and in dental schools throughout the world. ASDC J Dent Child 1989;56:426-34.
7. McDonald RE, Avery DR, Dean, JA: Dentistry for the Child and Adolescent, C.V. Mosby Co., St. Louis, 8th, 2004: pp406-7.
8. Irirricevic H, al-Jame Q. Ferric sulfate as pulpotomy agent in primary teeth: twenty month clinical follow-up. J Clin Pediatr Dent 2000;24:269-72.
9. Ribeiro DA, Matsumoto MA, Duarte MA, Marques ME, Salvadori DM. Ex vivo biocompatibility tests of regular and white forms of mineral trioxide aggregate. Int Endod J 2006;39:26-30.
10. Whitehead, A. Meta-analysis of controlled clinical trials. Wiley, Chichester; 1st Edition. 2002.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
12. Ribeiro DA, Matsumoto MA, Duarte MA, Marques ME, Salvadori DM. In vitro biocompatibility tests of two commercial types of mineral trioxide aggregate. Braz Oral Res 2005;19:183-7.
13. Koh ET, McDonald RE, Pitt Ford TR, Torabinejad M. Cellular response to Mineral Trioxide Aggregate. J Endod 1998;24:517.
14. Jabbarifar SE, Kardova AA, Ghasemi D. Success rates of Formocresol pulpotomy versus Mineral Trioxide aggregate in human primary molar teeth. J Res Med Sciences 2004; 6: 55-8.
15. Agamy HA, Bakry NS, Mounir MM, Avery DR. Comparison of mineral trioxide aggregate and formocresol as pulp-capping agents in pulpotomized primary teeth. Pediatr Dent 2004;26:302-9.
16. Kowsari A., Azadedel Sh., Akhondi N. Comparison between pulpotomy with MTA (made in Iran) and formocresol in primary molars of 3-6 years old children attending the department of pediatric dentistry, School of Dentistry, Medical Sciences/ University of Tehran in 2004. J Dental Medicine 2007;20:78-83 (Persian).
17. Eidelman E, Holan G, Fuks AB. Mineral trioxide aggregate vs. formocresol in pulpotomized primary molars: a preliminary report. Pediatr Dent 2001;23:15-8.
18. Willard RM. Radiographic changes following formocresol pulpotomy in primary molars. ASDC J Dent Child 1976;43:414-5.
19. Tziafas D, Smith AJ, Lesot H. Designing new treatment strategies in vital pulp therapy. J Dent 2000;28:77-92.
20. Ainehchi M, Dadvand S, Fayazi S, Bayat-Movahed S. Randomized controlled trial of mineral trioxide aggregate and formocresol for pulpotomy in primary molar teeth. Int Endod J 2007;40:261-7.
21. Farsi N, Alamoudi N, Balto K, Mushayt A. Success of mineral trioxide aggregate in pulpotomized primary molars. J Clin Pediatr Dent 2005;29:307-11.
22. Peng L, Ye L, Tan H, Zhou X. Evaluation of the formocresol versus mineral trioxide aggregate primary molar pulpotomy: a meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:e40-4.